1-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)-2-piperazinone | 921616-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)-2-piperazinone
• 英文别名: 1-{4-[3-(Azepan-1-yl)propoxy]phenyl}piperazin-2-one；1-[4-[3-(azepan-1-yl)propoxy]phenyl]piperazin-2-one
• CAS: 921616-74-2
• 化学式: C₁₉H₂₉N₃O₂
• 分子量: 331.458
• InChiKey: AHCDUSBWVXJWPQ-UHFFFAOYSA-N

物化性质

• 沸点：
  560.0±50.0 °C(Predicted)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)-2-piperazinone 、 4-甲砜基苯甲酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 1-[4-[3-(Azepan-1-yl)propoxy]phenyl]-4-(4-methylsulfonylbenzoyl)piperazin-2-one
  参考文献：
  名称：

  4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a Novel Class of Non-Brain-Penetrant Histamine H₃ Receptor Antagonists

  摘要：

  A series of ketopiperazines were prepared and evaluated for their activity as histamine H-3 antagonists. From investigation of the tertiary basic center in the aminopropyloxyphenyl template, the 2(R)-methylpyrrolidine was identified as the most potent amine. In the more rigid piperidineoxyphenyl template the N-cyclobutyl group was the most potent amine. The 4-fluorobenzyol, 4-cyanobenzoyl, and 2,4-difluorobenzoyl groups provided good pharmacokinetic profiles for the various amides. The PSA and log D values of these compounds suggested low brain penetration. The compounds had very high selectivity over other receptors and did not inhibit hepatic cytochrome P450, indicating low drug-drug interaction potential. Compound 22i was identified as the best compound of this series based on its overall profile of high potency, selectivity, low brain penetration, lack of CYP450 inhibition, high oral bioavailability, and pharmacokinetic properties.

  DOI：

  10.1021/jm0708228
• 作为产物：
  描述：

  1,1-dimethylethyl 4-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)-3-oxo-1-piperazinecarboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以97%的产率得到1-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)-2-piperazinone
  参考文献：
  名称：

  4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a Novel Class of Non-Brain-Penetrant Histamine H₃ Receptor Antagonists

  摘要：

  A series of ketopiperazines were prepared and evaluated for their activity as histamine H-3 antagonists. From investigation of the tertiary basic center in the aminopropyloxyphenyl template, the 2(R)-methylpyrrolidine was identified as the most potent amine. In the more rigid piperidineoxyphenyl template the N-cyclobutyl group was the most potent amine. The 4-fluorobenzyol, 4-cyanobenzoyl, and 2,4-difluorobenzoyl groups provided good pharmacokinetic profiles for the various amides. The PSA and log D values of these compounds suggested low brain penetration. The compounds had very high selectivity over other receptors and did not inhibit hepatic cytochrome P450, indicating low drug-drug interaction potential. Compound 22i was identified as the best compound of this series based on its overall profile of high potency, selectivity, low brain penetration, lack of CYP450 inhibition, high oral bioavailability, and pharmacokinetic properties.

  DOI：

  10.1021/jm0708228

文献信息

• Piperazinone Derivatives Useful as Histamine H3 Receptor Antagonists and/or Inverse Agonists
  申请人：Ancliff Rachael Ann

  公开号：US20080275027A1

  公开（公告）日：2008-11-06

  The invention relates to compounds of formula (I) or salts and solvates thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis: wherein R 1 and R 2 are as defined in the specification.

  本发明涉及式(I)的化合物或其盐和溶剂化物、其制备方法、含有它们的组合物以及它们在治疗各种疾病（如过敏性鼻炎）中的应用，其中R1和R2如规范中所定义。
• WO2007/9741
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] PIPERAZINONE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR ANTAGONISTS AND/OR INVERSE AGONISTS<br/>[FR] DERIVES DE PIPERAZINONE UTILES COMME ANTAGONISTES ET/OU AGONISTES INVERSES DES RECEPTEURS HISTAMINIQUES H3
  申请人：GLAXO GROUP LTD

  公开号：WO2007009741A1

  公开（公告）日：2007-01-25

  [EN] The invention relates to compounds of formula (I) or salts and solvates thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis, wherein R¹ and R² are as defined in the specification.
  [FR] L'invention concerne des composés représentés par la formule générale (I) ou des sels ou des solvates de ces composés, des procédés destinés à la préparation de ces composés, des compositions contenant ces composés et leur application dans le traitement de divers troubles, tels que la rhinite allergique. Dans la formule générale (I), R¹ et R² désignent des éléments définis dans la description.
• 4-Acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a Novel Class of Non-Brain-Penetrant Histamine H₃ Receptor Antagonists
  作者：Panayiotis A. Procopiou、Rachael A. Ancliff、Mark J. Bamford、Christopher Browning、Helen Connor、Susannah Davies、Yvonne C. Fogden、Simon T. Hodgson、Duncan S. Holmes、Brian E. Looker、Karen M. L. Morriss、Christopher A. Parr、Elizabeth A. Pickup、Sanjeet S. Sehmi、Gemma V. White、Clarissa J. Watts、David M. Wilson、Michael D. Woodrow

  DOI：10.1021/jm0708228

  日期：2007.12.27

  A series of ketopiperazines were prepared and evaluated for their activity as histamine H-3 antagonists. From investigation of the tertiary basic center in the aminopropyloxyphenyl template, the 2(R)-methylpyrrolidine was identified as the most potent amine. In the more rigid piperidineoxyphenyl template the N-cyclobutyl group was the most potent amine. The 4-fluorobenzyol, 4-cyanobenzoyl, and 2,4-difluorobenzoyl groups provided good pharmacokinetic profiles for the various amides. The PSA and log D values of these compounds suggested low brain penetration. The compounds had very high selectivity over other receptors and did not inhibit hepatic cytochrome P450, indicating low drug-drug interaction potential. Compound 22i was identified as the best compound of this series based on its overall profile of high potency, selectivity, low brain penetration, lack of CYP450 inhibition, high oral bioavailability, and pharmacokinetic properties.